Adoptive Chemoimmunotherapy Using Activated alpha beta T Cells for Stage IV Colorectal Cancer

作者：Yoshida Yoichiro^*; Naito Masayasu; Yamada Teppei; Aisu Naoya; Daibo Kojima; Mera Toshiyuki; Tanaka Toshihiro; Naito Keiko; Yasumoto Kosei; Kamigaki Takashi; Goto Shigenori; Yamashita Yuichi; Hasegawa Suguru

来源：Anticancer Research, 2016, 36(7): 3741-3746.

• Colorectal cancer
• chemotherapy
• immunotherapy
• XELOX
• alpha beta T

Background/Aim: Adoptive immunotherapy of cancer is evolving with the development of novel technologies that generate proliferation of large numbers of alpha beta and gamma delta T cells. We evaluated the safety and efficacy of the combination of adoptive immunotherapy using alpha beta T cells with chemotherapy for stage IV colorectal cancer (CRC). Patients and Methods: Fifteen patients with advanced or recurrent CRC received XELOX + bevacizumab + ex vivo expanded alpha beta T lymphocytes as a first-line chemoimmunotherapy. Results: Median age of the 15 patients (4 men, 11 women) was 65 years (range=49-80). Median progression-free survival was 21.3 months. Response rate was 80% (complete response (CR)=26.7%, partial response (PR)=53.3%, stable disease (SD)=20% and progressive disease (PD)=0%). Most adverse events were mild to moderate regarding their intensity and immunotherapy-associated toxicity was minimal. Conclusion: Combination of adoptive alpha beta T cell immunotherapy with chemotherapy for stage IV CRC is feasible and safe.

• 出版日期2016-7